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Background: Many of the systemic manifestations of chronic obstructive pulmonary disease 
(COPD) are mediated through increased systemic levels of inﬂ  ammatory proteins. We assessed 
the long term repeatability of Interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and 
C-reactive protein (CRP) over one year and examined the relationships between these systemic 
markers in COPD.
Methods: Fifty-eight stable COPD patients completed a baseline and one-year visit. Serum 
IL-6, plasma CRP, and plasma TNF-α were measured. Repeatability was expressed by intraclass 
correlation coefﬁ  cient (Ri) and the Bland–Altman method. Pearson correlations were used to 
determine the relationships between the systemic markers at both visits.
Results: There was moderate repeatability with a very high degree of statistical signiﬁ  cance 
(p  0.001) between the two visits for all the systemic biomarkers (IL-6, CRP, and TNF-α). CRP 
was signiﬁ  cantly associated with IL-6 at both visits (r = 0.55, p = 0.0001, r = 0.51, p = 0.0002, 
respectively). There were no other signiﬁ  cant associations between the systemic markers at 
either of the visits.
Conclusions: Systemic inﬂ  ammatory biomarkers IL-6, CRP, and TNF-α were moderately 
repeatable over a twelve month period in COPD patients. We have also shown that a robust 
and repeatable association between IL-6 and CRP exists.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a heterogeneous condition 
characterized by progressive airway inﬂ  ammation.1 It is well recognized that systemic 
manifestations are also a key component of COPD. These include increased levels 
of inﬂ  ammation in the blood,2,3 muscle inﬂ  ammation and wasting,4,5 cardiovascular 
disease,6 and osteoporosis.7 There is much interest in the use of biomarkers of systemic 
inﬂ  ammation in COPD, as these may have possible applications in disease phenotyping, 
monitoring of disease progression or exacerbations, and measuring the effects of 
therapeutic interventions.
It is believed that many of the systemic manifestations of COPD are mediated 
through increased systemic levels of inﬂ  ammatory proteins such as interleukin-6 
(IL-6), tumor necrosis factor-α (TNF-α) and C-reactive protein (CRP).2–4,8–12 CRP 
is a commonly used biomarker of systemic inﬂ  ammation in patients with COPD. 
Plasma CRP levels are increased in COPD patients2,3 and are associated with increased 
mortality.13,14 CRP levels are predictive of cardiovascular risk,15,16 and in patients 
with COPD also independently predict death due to COPD.13 CRP is also related to 
other important clinical outcomes including exercise tolerance,2,17 health status,2 and 
muscle strength.3 CRP is regulated by IL-6, as this cytokine can initiate an acute phase 
response through the induction of acute phase proteins including CRP in hepatocytes.18 International Journal of COPD 2009:4 150
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Consequently, it has been shown that IL-6 and CRP levels 
correlate in COPD patients.2,3,19,20
TNF-α has been shown to play a central role in the muscle 
wasting and weight loss seen in COPD patients9,21,22 and several 
studies have demonstrated increased levels of TNF-α and its 
receptors in the circulation of COPD patients.4,8,11,12,21 There is 
some evidence that TNF-α levels are related to levels of IL-63,19,23 
and CRP,3 although this has not been reported in all studies.2
CRP has previously been shown in a study by Pinto and 
colleagues17 to be repeatable over a 17 month period and 
even more recently both IL-6 and CRP have been shown to 
be repeatable over a six month period.24 However longer term 
studies of the repeatability of IL-6 and TNF-α are lacking. 
The repeatability of systemic biomarkers is an important 
issue, as those with increased variability will have less utility 
in clinical practice or research. Studies analyzing longer term 
repeatability are needed if systemic biomarkers are going to 
be used in long term observational studies or clinical trials 
of therapeutic interventions.
The main aims of this study were to 1) assess the long 
term repeatability of systemic biomarkers of inﬂ  ammation 
(CRP, TNF-α, IL-6) in COPD patients over one year, 2) to 
examine the relationships between these systemic markers 
and conﬁ  rm the results of previous studies in this area.
Methods
Subjects
Ninety-four stable patients were initially recruited into this 
single centre study from primary care by media advertising to 
the study at baseline (2004–2005), however only 58 patients 
returned for their follow up assessment (2005–2006). 
The 36 patients were lost to follow up as they either had 
withdrawn their consent or had not returned for their visit 
within the one-year timeframe. COPD was diagnosed accord-
ing to current Global Initiative for Chronic Obstructive Lung 
Disease (GOLD) guidelines,1 based on a smoking history of 
at least 10 pack-years with typical symptoms (one or more 
of productive cough, breathlessness, and wheeze) and evi-
dence of airﬂ  ow obstruction. Patients with a clinical history 
of asthma, alpha-1-antitrypsin deﬁ  ciency, an exacerbation or 
any change in their COPD therapy within four weeks of the 
study at the baseline and the one-year visit, or a history of lung 
cancer were excluded. Written informed consent was obtained 
and the local ethics committee approved the study.
Study design
Spirometry, sputum induction, and peripheral blood sam-
pling were performed at the baseline visit and then repeated 
one year later. Sputum differential cell counts were performed 
and IL-8 was measured in the sputum supernatant to charac-
terize airway inﬂ  ammatory biomarkers. Serum IL-6, plasma 
CRP, and plasma TNF-α were measured at both visits as 
biomarkers of systemic inﬂ  ammation. Height was measured 
to the nearest cm and weight to the nearest 100 gm. Body 
mass index (BMI) was calculated as weight in kg divided by 
squared height in meters.
Spirometry
Maximum expiratory flow volume measurements were 
performed using the spirometry system on the MasterScreen 
(Jaeger GmbH, Würzburg, Germany). Forced expiratory 
volume in one second (FEV1) and forced vital capacity 
(FVC) readings were performed in triplicate. Spirometry 
during sputum induction was performed with a Vitalograph 
spirometer (Vitalograph, Buckinghamshire, UK). The equip-
ment was calibrated daily according to the manufacturer’s 
instructions.
Plasma and serum assays
Plasma and serum were obtained from peripheral blood 
samples by centrifugation for 15 minutes, at 1500 g and 
at 4 °C or ambient temperature, respectively. Plasma and 
serum samples were stored at −80 °C until analysis. Plasma 
TNF-α and serum IL-6 was measured by high sensitivity 
ELISA (Quantikine, R&D Systems Europe, Oxon, UK) 
with a lower limit of detection of 0.5 pg/ml and 0.156 pg/ml 
respectively. Serum was used for the IL-6 assay as there 
was insufﬁ  cient plasma available from all patients. Plasma 
CRP was measured by high sensitivity particle-enhanced 
immunonephelometry (Cardiophase; BN systems, Dade 
Behring, Newark, NJ, USA) with a lower limit of detection 
of 0.175 mg/L.
Statistical analysis
The Kolmogorov – Smirnov test determined normality of the 
data and nonparametric data were natural log transformed. 
Naturally log-transformed data was therefore used for IL-6, 
CRP, and TNF-α for our anlaysis.
Paired t test was performed to determine the mean 
differences between the baseline and one-year visit. Repeat-
ability was expressed as an intraclass correlation coefﬁ  cient 
(ICC) [Ri = between-subject variance/ (within- + between-
subject variance)]. P  0.05 was considered statistically 
signiﬁ  cant. Ri values of 0 to 0.2 are usually interpreted to 
indicate slight repeatability, 0.21 to 0.40 to indicate fair 
repeatability, 0.41 to 0.60 to indicate moderate repeatability, International Journal of COPD 2009:4 151
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0.61 to 0.8 to indicate good repeatability, and 0.81 to 1.00 
to indicate very good repeatability. Graphical representation 
of repeatability between the two visits were reported using 
the Bland – Altman method.30 The limits of agreement are 
expressed as ± 2 standard deviations (SD) of the mean of 
differences betweeen the two measurements within which 
95% of the repeated measures are expected to lie and for 
our naturally log-transformed data the limits of agreement 
were antilogged to express the fold changes expected over 
a one-year period.
Pearson correlations were used to determine the 
relationships between the systemic markers at both the base-
line and one-year visit. Statistical analyses were performed 
using SPSS (SPSS Inc., Chicago, IL, USA) and GraphPad 
(GraphPad Software, Inc., La Jolla, CA, USA) software.
Previous publications studying the repeatability of 
sputum biomarkers,25–29 plasma IL-6,24 and CRP17 used 
varying sample sizes from 10–88 COPD patients. Thus, we 
enrolled 94 subjects, and considered that the matched data 
from the returning 58 COPD patients who had both baseline 
and one-year measurements was an adequate sample size 
for this study.
Results
The study population was composed of 58 subjects, with 
40 patients categorized as GOLD stage 2, 15 patients as 
stage 3, and 3 patients at stage 4 (see Table 1 for demography). 
FEV1 percent predicted did not change over the one-year 
period (mean 56.7 vs 57.5, p = 0.1) (Figure 1) and neither 
did BMI (mean 27.45 vs 27.31, p = 0.4). Table 2 shows the 
baseline and one-year values for other pulmonary function 
tests. Peripheral blood samples were obtained from all 
58 patients at both visits.
Repeatability of systemic biomarkers
Table 3 summarizes the measurements of the systemic 
inﬂ  ammatory biomarkers and BMI at the baseline and one-
year visit. Using paired T tests there was no statistically 
signiﬁ  cant change in these measurements between both visits 
(p  0.05 for all comparisons).
Using ICC analysis, there was moderate agreement with 
a very high degree of statistical signiﬁ  cance (p  0.001) 
between the two visits for all the systemic biomark-
ers (IL-6, CRP, and TNF-α). Graphical representations 
of the repeatability of systemic biomarkers using the 
Bland – Altman methods are shown in Figure 2. These plots 
indicate moderate reproducibility, as the mean differences 
of the repeated measurements lie close to zero and all values 
are randomly scattered around the mean difference with 
the majority of values lying within the limits of agreement 
(±2 SD). Antilogging the limits for IL-6, CRP, and TNF-α 
show that 95% of cases for the one-year measurement will 
have at least a 3.8-, 5.2-, and 2.8-fold change from the 
baseline measurement, respectively.
Relationships between systemic 
biomarkers
CRP was signiﬁ  cantly associated with IL-6 at the baseline 
and one-year visits (r = 0.55, p = 0.0001, r = 0.51, p = 0.0002, 
respectively) (Figures 3a, 3b). There were no other signiﬁ  cant 
associations between the systemic markers at either of the 
visits (Tables 4a, 4b).
Discussion
The main novelty of this study is the repeatability of systemic 
biomarkers in a moderate to severe COPD population over 
one-year. IL-6, CRP, and TNF-α showed moderate repeat-
ability over one year. We also found a moderate association 
between CRP and IL-6, conﬁ  rming the results of previous 
studies,2,3,19,20 but no association between these proteins and 
TNF-α, in contrast to previous reports.3,19,23
The repeatability of systemic inﬂ  ammatory biomark-
ers over 12 months in COPD patients was analyzed by 
three statistical methods; ﬁ  rst, we observed no signiﬁ  cant 
changes in group mean values for any of the measurements. 
Table 1 Baseline characteristics of the study patients
Characteristic n = 58 COPD
Age (years) 63.78 (8.32)
Gender, male/female 40/18
Current/Ex-smokers 23/35
Pack year historya 42.5 (36–53.5)
Inhaled steroids use/no use 31
Long acting beta agonist use 27
Long acting anticholinergic use 10
Methylxanthines use 5
Pre-bronchodilator FEV1 % predicted 56.71 (13.11)
Pre-bronchodilator FVC % predicted 93.64 (17.77)
Post-bronchodilator FEV1 % predicted 64.09 (14.16)
Post bronchodilator FEV1 (L) 1.79 (0.6)
Post bronchodilator FEV1/FVC ratio (%) 51.39 (10.05)
Abbreviations: COPD, chronic obstructive pulmonary disease; FEV1, forced 
expiratory volume in one second; FVC, forced vital capacity; IQR, interquartile range; 
SD, standard deviation.
Notes: Lung function measurements were standardized for age and gender. There 
were no patients on oral corticosteroids. Results presented as mean (SD) or median 
(IQR).International Journal of COPD 2009:4 152
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Second, using ICC, which is a recognized method for 
assessing the repeatability of measurements, we observed 
moderate levels of agreement for systemic inﬂ  ammatory 
markers, as the Ri values were 0.5. Third, we also pres-
ent Bland – Altman plots to view the repeatability of data 
from individual subjects. To our knowledge, this is the ﬁ  rst 
study to compare the long term reproducibility of IL-6 and 
TNF-α in COPD patients, and we demonstrate moderate 
repeatability for these systemic biomarkers over a 12 month 
period.
It has previously been shown that CRP did not change 
over a 17 month interval,17 but we are not aware of any similar 
information concerning IL-6 and TNF-α. The assessments 
of repeatability in our study can be used in the following 
ways; the within-subject SDs can be used to aid the statistical 
powering of clinical trials with pharmacological interven-
tions and the Bland–Altman plots show the variation that 
could be expected for individual measurements in clinical 
practice.
The systemic biomarkers that we investigated all 
appear to be related to pathophysiological processes in 
COPD; CRP is related to cardiovascular risk15,16 and has 
been shown to be associated with many other important 
clinical outcomes of COPD. For example previous studies 
have been shown CRP to be related to the symptom domain 
of St George’s Respiratory Questionnaire (SGRQ), impaired 
energy metabolism, and muscle strength.2,3,17 IL-6 is known 
as a powerful promoter of CRP production in the liver18 and 
is associated with CRP levels in COPD patients,2,3,6,19 whilst 
TNF-α and its receptors are increased in the muscles of COPD 
patients thus implicating it in conditions such as cachexia in 
COPD.4,31,32
The present study conﬁ  rms that the link between IL-6 and 
CRP exists in our group of moderate to severe COPD patients 
and that it is a robust relationship that does not change over 
one year. The moderate association (r = 0.51–0.55) on two 
occasions adds conﬁ  dence to our interpretation that IL-6 
promotes CRP production in COPD patients.
The ﬁ  nding that neither IL-6 nor CRP was related to the 
TNF-α is in contrast to two previous studies that showed a 
relationship, albeit a weak correlation, between TNF-α and 
IL-63,19 and TNF-α and CRP existed3 in COPD patients. One 
methodological explanation for the lack of correlation in the 
current study could be due to the short half life of TNF-α 
compared to IL-6 or CRP. TNF-α has a short half-life of a 
few minutes and is also difﬁ  cult to detect because it forms 
complexes with soluble TNF-α receptors (sTNF-R) and has 
high renal clearance.33,34 Circulating sTNF-R may be a more 
sensitive marker of TNF-α activation as they have slower 
renal clearance.33,34 Increased levels of these soluble recep-
tors have been detected in COPD patients.11,21 In addition 





































Figure 1 FEV1 % predicted for each patients at the baseline and year 1 visit.
Table 2 Pulmonary function at the baseline visit and one-year visit
Pulmonary function Baseline Year 1
Pre-bronchodilator FEV1 % predicted 56.71 (13.1) 57.49 (13.2)
Post-bronchodilator FEV1 % predicted 64.09 (14.2) 63.63 (14.9)
Rawa (kPa.sec) 0.46 (0.4–0.5) 0.47 (0.4–0.5)
sGawa (kPa.sec) 0.46 (0.4–0.5) 0.47 (0.4–0.5)
FRC (% predicted) 132.02 (29.0) 128.17 (30.5)
IC (L) 2.33 (0.6) 2.40 (0.6)
TLC % predicted 106.44 (16.2) 103.11 (15.2)
RV % predicted 147.27 (35.8) 131.16 (41.3)
KCO % predicted 89.49 (25.1) 89.08 (24.8)
Abbreviations: CI, conﬁ  dence interval; FEV1, forced expiratory volume in one second; FRC, functional residual capacity; IC, inspiratory capacity; KCO, carbon monoxide 
diffusion factor; Raw, airways resistance; RV, residual volume; SD, standard deviation; sGaw, speciﬁ  c airways conductance;   TLC, total lung capacity.
Notes: Lung function measurements were standardized for age and gender. There were no patients on oral corticosteroids. Results presented as mean (SD) or geometric 
mean (95% CI).International Journal of COPD 2009:4 153
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COPD patients and a different relationship to TNF-α may 
have been observed in a population consisting of a range of 
disease severities.
BMI is recognized as an important tool in deﬁ  ning 
phenotypes of COPD patients and a reduced BMI has 
been shown to be an independent risk factor for mortality 
in COPD and to be associated with disease severity.35,36 
Increased skeletal muscle apoptosis have also been shown 
to be associated with a lower BMI and reduced exercise 
tolerance.5 In our study BMI was not related to circulating 
levels of IL-6, CRP, and TNF-α. This suggests that body 
mass loss may not be caused through systemic inﬂ  amma-
tion. However, there are studies that have shown CRP and 
BMI to be associated to each other.2,4,17 These ﬁ  ndings 
were found in severe COPD patients with FEV1  40% 
in comparison to the current study population comprised 
mainly of moderate disease. Although, in one recent study 
by Karadag and colleagues37 moderate patients were grouped 
into low BMI and normal-to-high BMI and they showed 
that the low BMI patients had higher levels of CRP and 
TNF-α. Conversely, in our population of patients we did not 
observe signiﬁ  cant weight loss in individual patients over 
one-year, with our mean values of BMI being 25 kg/m2 
at both visits. This perhaps could also account for the lack 
of correlation observed between change in BMI and inﬂ  am-
matory biomarkers.
TNF-α and IL-6 levels have been shown to be increased 
in weight losing COPD patients4,9 However the present 
study does not support this ﬁ  nding. In the study by Eid 
and colleagues,4 weight loss characterized by reduced fat 
free mass (FFM) and skeletal muscle mass was associated 
with increased systemic inﬂ  ammatory response. They 
showed that TNF-α, sTNF-R, and IL-6 were inversely 
related to FFM in patients with normal BMI. Another 
study also showed that CRP was inversely related to FFM 
in hypermetabolic patients.8 FFM appears to be a better 
marker of weight loss compared to BMI, particularly since 
FFM has been shown to be a predictor of mortality in 
the presence of normal BMI.38 BMI has the advantage of 
being easy to measure but is a limited value as it does not 
Table 3 Repeatability of systemic measurements over the one year interval
Systemic indices Baseline Year 1 p value Ri and p value
IL-6 (pg/ml) 3.2 (2.5–4.1) 3.1 (2.6–3.7) 0.75 0.50 0.001
CRP (pg/ml) 3.3 (2.5–4.4) 2.9 (2.3–3.6) 0.57 0.57 0.0001
TNF-α (pg/ml) 1.8 (1.6–2.0) 1.6 (1.4–1.9) 0.41 0.57 0.0001
Abbreviations: CRP, C-reactive protein; IL-6, interleukin-6;   TNF-α, tumor necrosis factor-α.
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Figure 2 Bland–Altman plots for a) IL-6, b) CRP and c) TNFα collected with a one year 
interval.   The dotted lines represent the mean difference ± 2 SD. 
Abbreviations: CRP, C-reactive protein; IL, interleukin; TNFα, tumor necrosis 
factor-α.International Journal of COPD 2009:4 154
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Table 4a Relationships between systemic inﬂ  ammatory biomarkers 
and BMI at the baseline visit
CRP TNF-α BMI
IL-6 r = 0.55, p = 0.0001 r = 0.11, p = 0.47 r = −0.10, p = 0.49
CRP r = 0.18, p = 0.20 r = 0.18, p = 0.22
TNF-α r = −0.11, p = 0.44
Abbreviations: BMI, body mass index; CRP, C-reactive protein; IL-6, interleukin-6; 
TNF-α, tumor necrosis factor-α.
Table 4b Relationships between systemic inﬂ  ammatory biomarkers 
and BMI at the one-year visit
CRP TNF-α BMI
IL-6 r = 0.51, p = 0.0002 r = 0.18, p = 0.23 r = 0.25, p = 0.09
CRP r = −0.11, p = 0.41 r = 0.26, p = 0.06
TNF-α r = −0.20, p = 0.16
Abbreviations: BMI, body mass index; CRP, C-reactive protein; IL-6, interleukin-6; 



































r = 0.55, p = 0.0001 
4 3 12 0 –1 –2  
Figure 3a The relationship between CRP and IL-6 at the baseline visit.
































r = 0.51, p = 0.0002 
4 3 2 1 0 –1 –2 
Figure 3b The relationship between CRP and IL-6 at the one-year visit.
Abbreviations: CRP, C-reactive protein; IL-6, interleukin-6.
represent changes in body composition or reﬂ  ect skeletal 
muscle depletion.
The limitations of our study are: (a) we did not measure 
many other systemic biomarkers that may be of interest in 
COPD due to limited resources and therefore we decided to 
measure IL-6, CRP, and TNF-α because of their potential 
role in the pathopyhysiology of COPD; (b) we measured 
our samples only once at enrollment and at 12 months. 
It would have been of interest to have performed “serial 
sampling”; a recent study39 using 11 visits performed over International Journal of COPD 2009:4 155
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a one-month interval to assess inﬂ  ammatory biomarkers 
suggests that intra-patient variability is reduced with the 
use of a “rolling mean” of serial samples; (c) our popula-
tion was composed of mainly moderate-to-severe disease, 
and the inclusion of more very severe patients would have 
been of interest especially to examine the repeatability 
by different GOLD severities; (d) we did not capture any 
clinical changes such as exacerbation within in the one-
year interval excluding the four-week interval leading up 
to their study visit which may have inﬂ  uenced our results; 
(e) we were unable to perform analysis related to changes 
in therapeutic regime as we were limited by numbers of 
patients that had actually had a change in their medications 
such as stopping/starting inhaled corticosteroids (ICS) by 
the one-year visit. Although, it has recently been conﬁ  rmed 
by Sin and colleagues40 and Kuniaski and colleagues20 that 
ICS use does not affect IL-6 and CRP levels measured; 
and (f) we did not relate our ﬁ  ndings to other clinical 
parameters of COPD such as partial pressure of oxygen in 
arterial blood, exercise tolerance, and health status over an 
one-year interval.
In conclusion, the systemic inﬂ  ammatory biomarkers 
IL-6, CRP, and TNF-α were moderately repeatable over a 
12 month period in COPD patients. We have also shown that 
a robust and repeatable association between IL-6 and CRP 
exists. However, there was a lack of correlation of TNF-α 
to IL-6 or CRP, possibly due to the instability of TNF-α, or 
perhaps because TNF-α genuinely plays a different role to 
IL-6 and CRP in the pathophysiology of COPD.
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